ProPhase Labs, Inc. (NASDAQ:PRPH) Short Interest Down 31.2% in April

ProPhase Labs, Inc. (NASDAQ:PRPHGet Rating) was the recipient of a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 71,000 shares, a drop of 31.2% from the March 31st total of 103,200 shares. Based on an average daily volume of 25,000 shares, the short-interest ratio is currently 2.8 days. Approximately 0.6% of the company’s shares are short sold.

A number of equities analysts recently weighed in on the stock. HC Wainwright increased their price objective on shares of ProPhase Labs from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, March 31st. StockNews.com began coverage on shares of ProPhase Labs in a research report on Wednesday. They issued a “sell” rating for the company. TheStreet raised shares of ProPhase Labs from a “d+” rating to a “c-” rating in a research report on Monday, March 28th. Finally, Zacks Investment Research raised shares of ProPhase Labs from a “hold” rating to a “buy” rating and set a $7.75 price target for the company in a research report on Tuesday, February 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, ProPhase Labs has an average rating of “Hold” and a consensus price target of $11.88.

Several institutional investors and hedge funds have recently made changes to their positions in PRPH. Avidian Wealth Solutions LLC raised its holdings in shares of ProPhase Labs by 91.4% in the 3rd quarter. Avidian Wealth Solutions LLC now owns 105,202 shares of the company’s stock valued at $547,000 after purchasing an additional 50,239 shares in the last quarter. Millennium Management LLC raised its holdings in shares of ProPhase Labs by 165.1% in the 2nd quarter. Millennium Management LLC now owns 46,575 shares of the company’s stock valued at $289,000 after purchasing an additional 29,008 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of ProPhase Labs in the 2nd quarter valued at $177,000. Marshall Wace LLP acquired a new stake in shares of ProPhase Labs in the 3rd quarter valued at $119,000. Finally, HighVista Strategies LLC acquired a new stake in shares of ProPhase Labs in the 3rd quarter valued at $105,000. Institutional investors and hedge funds own 10.64% of the company’s stock.

Shares of PRPH opened at $7.42 on Friday. ProPhase Labs has a twelve month low of $4.44 and a twelve month high of $8.58. The firm’s fifty day simple moving average is $7.16 and its 200-day simple moving average is $6.84. The firm has a market capitalization of $114.94 million, a price-to-earnings ratio of 19.03 and a beta of 0.01. The company has a current ratio of 3.95, a quick ratio of 3.65 and a debt-to-equity ratio of 0.17.

The company also recently disclosed a dividend, which was paid on Thursday, March 10th. Stockholders of record on Tuesday, March 1st were issued a $0.30 dividend. The ex-dividend date was Monday, February 28th.

About ProPhase Labs (Get Rating)

ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.

Further Reading

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.